Across all CI claims for men, the male-specific cancers accounted for 13 per cent of claims, with prostate cancer at 6.7 per cent and testicular cancer at 6.5 per cent.
Figures from the insurer show that it paid almost £8m during 2012 to men with these conditions, with an average payout of more than £81,000.
The cancers accounted for 14 per cent of all Aviva private medical insurance claims, with the insurer funding treatments of £5.9m for prostate cancer and £321,000 for testicular cancer.
Since October 2011 an additional benefit has been added to Aviva’s CI cover which means that customers with low-grade prostate cancer can receive up to £20,000 while their policy is in force.
David Penny, managing director of Somerset-based Invest Southwest, said: “CI is very important and forms part of a triumvirate of protection products with life and income protection. However the recent regulatory changes mean that there are fewer advisers to sell it. Another problem is that it’s normally the first to be dropped in straitened times as it’s much more expensive than other protection products.”